The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 354:1206-1208 March 16, 2006 Number 11
NextNext

Safety of Long-Acting Beta-Agonists

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Martinez, F. D.
-PubMed Citation
To the Editor: The recommendation in the Perspective article by Martinez (Dec. 22 issue)1 of adding leukotriene modifiers or theophylline to therapy for asthma that is not controlled with the use of inhaled corticosteroids is completely opposite to that of the National Asthma Education and Prevention Program expert panel, which prefers the addition of long-acting beta-agonists.2 A Cochrane review showed that adding long-acting beta-agonists, instead of leukotriene modifiers, to the treatment of asthma not controlled by inhaled corticosteroids would prevent one exacerbation for every 38 patients treated.3 If only 25 percent (thought to be a large underestimate4) of the . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.